Pulse Biosciences Inc

Pulse Biosciences insider buying signals confidence amid cash‑run challenges—what investors should watch for the future of its nPulse system.

Pulse Biosciences CTO Darrin Ueker receives 100,000 RSUs, signaling management confidence and long‑term alignment with shareholders amid growth‑stage medical device innovation.

Pulse Biosciences insider trading shows CEO Danahy’s disciplined confidence, buying near 52‑week highs while managing liquidity, signaling a potential commercial upswing.